key: cord-0969084-mxnhm5av
authors: Bommireddy, Ramireddy; Stone, Shannon; Bhatnagar, Noopur; Kumari, Pratima; Munoz, Luis E.; Oh, Judy; Kim, Ki-Hye; Berry, Jameson T. L.; Jacobsen, Kristen M.; Jaafar, Lahcen; Naing, Swe-Htet; Blackerby, Allison N.; Gaag, Tori Van der; Wright, Chloe N.; Lai, Lilin; Pack, Christopher D.; Ramachandiran, Sampath; Suthar, Mehul S.; Kang, Sang-Moo; Kumar, Mukesh; Reddy, Shaker J. C.; Selvaraj, Periasamy
title: Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses
date: 2022-02-01
journal: bioRxiv
DOI: 10.1101/2022.02.01.478657
sha: b10649017c73763e228bc8801dcf1e1784389115
doc_id: 969084
cord_uid: mxnhm5av

Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the influence of immune responses induced by other vaccinations on the durability and efficacy of the immune response to SARS-CoV-2 vaccine is still unknown. We have developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 S1 RBD fused to GM-CSF as an adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the hybrid vaccine induced a strong antibody response and protected mice from both influenza virus and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung viral titers compared to naive mice. These results suggest that the hybrid vaccine strategy is a promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV-2 infections.

Abstract: 22 Several approaches have produced an effective vaccine against severe acute respiratory 23 syndrome coronavirus 2 (SARS-CoV-2). However, the influence of immune responses induced 24 by other vaccinations on the durability and efficacy of the immune response to SARS-CoV-2 25 vaccine is still unknown. We have developed a hybrid vaccine for SARS-CoV-2 and influenza 26 viruses using influenza virus-like particles (VLP) incorporated by protein transfer with 27 glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 S1 RBD fused to GM-CSF as an 28 adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and 29 incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the 30 hybrid vaccine induced a strong antibody response and protected mice from both influenza virus 31 and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower 32 lung viral titers compared to naive mice. These results suggest that the hybrid vaccine strategy is 33 Introduction 37 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first appeared in late 2019 38 in China before beginning its rapid spread across the globe (1). The disease, named COVID-19, 39 presents a severe respiratory disease course and high fatality rate in the elderly and 40 immunocompromised (2). The spike (S) protein of the virus binds to the human ACE2 protein 41 for entry into epithelial cells of the respiratory tract (1, 3). This S protein, and specifically the 42 conserved ACE2 receptor-binding domain (RBD), is a proven target for vaccine design. 43 Antibodies and vaccines directed to the S protein and the RBD are effective in preventing SARS- 44 CoV-2 infection (4). Virtually all recent vaccine strategies for SARS-CoV-2 target the full- 45 length S protein (Pfizer/BioNTech, Moderna, Johnson & Johnson, AstraZeneca/Oxford, 46 Novavax, Innovio, Curevac, and others) (5, 6). 47 uses an antigen fused to GM-CSF that delivers antigen effectively to the immune system (17, 60 18). Adjuvants that have a tolerable safety profile and generate a Th1 immune response are of 61 high importance. Moreover, proinflammatory cytokines produced by activated dendritic cells 62 (DCs) have been shown to play an important role in inducing a robust immune response (19, 20) . 63 IL-12 has been well documented to induce a Th1 response, with a promising clinical benefit in 64 cancer patients (8). IL-12, a heterodimeric cytokine (p35 and p40 subunits), activates DCs, T of adjuvant and antigen source leads to simultaneous adjuvant and antigen delivery to immune 83 cells, resulting in enhanced immune reactivity and increased vaccine efficacy when compared to 84 unconjugated antigen and adjuvant mixture (37, 38). In the present study, we demonstrate that 85 influenza VLP vaccine incorporated with GPI-RBD-GM-CSF fusion protein and GPI-IL-12 86 (hybrid vaccine) protected mice from influenza virus challenge and also induced a robust, 87 durable antibody response in BALB/c mice as well as decreased viral load and less weight loss 88 when challenged with mouse adapted SARS-CoV-2. 89 

Characterization of GPI-RBD-GM-CSF fusion protein 92 We constructed a fusion protein gene by joining the DNA sequences specific to SARS CoV-2 S 93 protein RBD domain, mouse GM-CSF sequence and the GPI-anchor signal from human CD59 Figure 1B ). To verify whether the GPI-RBD-GM-CSF fusion protein contains the GPI tail, 97 CHO-S cells expressing the fusion protein were incubated with phosphatidylinositol-specific 98 phospholipase C (PIPLC), which is known to cleave the GPI moiety from the proteins and 99 release them from the cell membranes, and then analyzed by flow cytometry. The results show 100 that nearly 76% of the fusion protein was released from the cell surface, suggesting that the human ACE2 confirmed that the RBD in purified GPI-RBD-GM-CSF fusion protein retains its 129 receptor binding activity ( Figure 2C ). 130 To make the VLP hybrid vaccine, we incorporated the influenza VLPs with GPI-IL-12 and Biotech) or PBS. Booster dose was given 2-4 weeks after the first dose. The route of 149 administration was either subcutaneous (s.c.) or intramuscular (i.m.) (Fig. S2) . 150 Blood was collected every 2 to 4 weeks for antibody titer, ACE2 binding inhibition, and virus 151 neutralization assays. VLP vaccine incorporated with GPI-RBD-GM-CSF and GPI-IL-12 (hybrid 152 vaccine) induced robust antibody response after the booster dose (Fig. S3 ). The antibody 153 response against GPI-RBD-GM-CSF fusion protein was comparable in both i.m. and s.c. routes 154 of vaccine administration (Fig. S4) . The antibodies bind to CHO-S cells expressing the GPI- Hybrid vaccine induces IgG2a antibody response 177 We observed that purified GPI-RBD-GM-CSF fusion protein by itself or incorporated onto VLPs 178 induced a strong antibody response ( Figure 3A ). However, recombinant RBD-His tag failed to 179 induce an antibody response suggesting that the GM-CSF in our fusion protein is acting as an Figure 4C ). This may be because GPI-GM-CSF is more active than GPI-RBD-203 GM-CSF or may be due to the difference in the level of incorporation onto VLP or both, which 204 need further investigation. 243 We have demonstrated that a hybrid vaccine based on influenza VLPs induces effective 244 immunity against SARS-CoV-2 and influenza viruses. Our vaccine platform is based on cytokine 245 adjuvants linked to the VLPs that carry the antigens (7). This approach delivers both antigens 246 and biological adjuvants to the immune system simultaneously in a particulate form. We have 247 generated CHO-S cells expressing GPI-anchored spike RBD-GM-CSF fusion protein and GPI- In some experiments, Spike S1 protein from commercial sources (RayBiotech or Sino 416 Biologicals) was used as indicated in the figure legends. Plates were washed using a plate washer 417 and washing buffer (PBS with 0.05% Tween20). Plates were blocked with assay diluent (PBS 418 with 3% BSA) for 2 hours at room temperature on a rocker. Plates were washed again as above 419 and diluted serum samples were added and incubated for another 2 hours at room temperature. 

Incorporation of glycosylphosphatidylinositol-anchored GM-CSF or CD40 ligand 614 enhamces immunogenicity of chimeric simian immunodeficiency virus-like particles

Co-delivery of GM-CSF gene 617 enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: 618 role of dendritic cells

Differences in dendritic 621 cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-622 stimulating factor or Flt3-ligand

GPI-anchoring of GM-CSF results in 625 active membrane-bound and partially shed cytokine

Incorporation of glycosylphosphatidylinositol-anchored granulocyte-macrophage 629 colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian 630 immunodeficiency virus-like particles

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 639 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

Dendritic cells and cytokines in human 643 inflammatory and autoimmune diseases

CD4 T cell defects in the aged: causes, 647 consequences and strategies to circumvent

Immunotherapy of cancer

Immune response against large 680 tumors eradicated by treatment with cyclophosphamide and IL-12

IL-12 deaths: explanation and a puzzle

The IL-27R (WSX-1) is required to suppress T cell hyperactivity during 686 infection

Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored 689

T-cell therapy in murine tumor models

Cancer 693 immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and 694 cytoplasmic domains

Custom designing therapeutic cancer 697 vaccines: Delivery of immunostimulatory molecule adjuvants by protein transfer. Human 698 Vaccines

Influenza virus-like 700 particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity

Potent immunogenicity and efficacy of a 705 universal influenza vaccine candidate comprising a recombinant fusion protein linking 706 influenza M2e to the TLR5 ligand flagellin

Uptake of human papillomavirus virus-like 709 particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition 710 of T cell immunity

Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing 715

Current protocols in immunology

Mosaic 720 nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

SARS-CoV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice

Plasma membrane vesicles decorated with glycolipid-728 anchored antigens and adjuvants via protein transfer as an antigen delivery platform for 729 inhibition of tumor growth

An advanced 732 culture method for generating large quantities of highly pure dendritic cells from mouse bone 733 marrow

Virus-like particle vaccine induces protective 735 immunity against homologous and heterologous strains of influenza virus

Mucosal adjuvants for 739 influenza virus-like particle vaccine

Shi 743 PY. An Infectious cDNA Clone of SARS-CoV-2

Viridot: An automated virus plaque (immunofocus) counter for the measurement of 749 serological neutralizing responses with application to dengue virus

Rapid identification of a human antibody with high 755 prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection

Mouse-Adapted SARS-CoV-2 Induces

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT 765 ENDPOINTS12

C) PIPLC 774 treatment of CHO-S cells expressing GPI-RBD-GM-CSF reduced the level of expression, and 775 (D) Flow cytometry analysis showed binding of human ACE-2 to GPI-RBD-GM-CSF

Figure 2. Purified GPI-RBD-GM-CSF fusion protein retains functional activity

Colloidal blue (lane 1), and Western blot (lanes 2-7) of the immunoaffinity column purified 780 fusion protein from CHO-S cells probed with anti-RBD antibody (lanes 3 & 4)

Lane 2 is control RBD probed with anti-RBD Ab, and lane 5 is control GM-782 CSF probed with anti-GM-CSF antibody. (B) ELISA for GPI-RBD-GM-CSF binding to 783 antibodies in the human COVID-19 patients' sera, and (C) ELISA of purified GPI-RBD-GM-784 CSF binding to ACE-2. (D) FACS analysis of VLPs incorporated with

CSF fusion protein by protein transfer, and (E) BMDC proliferation by GPI-GM-CSF, 786 GPI-RBD-GM-CSF and hybrid vaccine

VLP RG: VLP incorporated with GPI-RBD-GM-CSF; hybrid vaccine: VLP 817 incorporated with GPI-RBD-GM-CSF and GPI-IL-12

Lung viral titer (B) and survival (C) of mice 823 challenged with influenza A/PR8 H1N1 virus 3 months after the booster dose. Inoculation dose 824 was 10 times LD50. VLP RG: VLP incorporated with GPI-RBD-GM-CSF; Hybrid vaccine: VLP 825 incorporated with GPI-RBD-GM-CSF and GPI-IL-12. Statistical significance was calculated by 826 one-way ANOVA and Dunnett's post-multiple comparison tests